Prognosis for Invasive Ductal Carcinoma of the Breast

Key Prognostic Factors

Invasive ductal carcinoma represents 70-75% of all invasive breast cancers and has varying prognosis based on molecular subtype, according to the American Society of Clinical Oncology 1
Tumor grade significantly impacts prognosis, with higher grade tumors having worse outcomes, as reported by the National Comprehensive Cancer Network 1, 2
Presence of lymphovascular invasion is associated with increased risk of recurrence, as noted by the American Cancer Society 3
Tumor necrosis and inflammatory infiltrate may be associated with poorer outcomes, as reported by the American Cancer Society 3
Special histologic subtypes of IDC, such as mucinous, tubular, and adenoid cystic, have particularly favorable prognoses compared to standard IDC, according to the National Comprehensive Cancer Network 2

Tumor size is a principal risk factor for lymph node involvement and subsequent prognosis, as reported by the British Journal of Cancer 4
Axillary lymph node status remains one of the strongest prognostic indicators, according to the American Society of Clinical Oncology 1, 4
The number of positive lymph nodes (≥4) significantly worsens prognosis, as noted by the British Journal of Cancer 4
Positive surgical margins increase risk of local recurrence and may impact overall survival, as reported by the American Cancer Society 3, 4

Young age (under 35-40 years) is associated with worse prognosis, as reported by the British Journal of Cancer 4, 3
Premenopausal status may be associated with more aggressive disease, according to the British Journal of Cancer 4

Pathological diagnosis should follow World Health Organization (WHO) classification and American Joint Committee on Cancer (AJCC) TNM staging system, as recommended by the American Society of Clinical Oncology 1
Hormone receptor status should be determined in all cases using standardized assessment methodology, according to the American Society of Clinical Oncology 1, 4
HER2 status should be evaluated according to American Society of Clinical Oncology-College of American Pathologists (ASCO-CAP) guidelines, as recommended by the American Society of Clinical Oncology 1
Proliferation markers such as Ki67 labeling index provide additional prognostic information, as reported by the American Society of Clinical Oncology 1

Failure to obtain adequate tissue sampling may lead to inaccurate assessment of tumor biology, as noted by the American Society of Clinical Oncology 1
Incomplete pathology reporting can miss critical prognostic elements, according to the National Comprehensive Cancer Network 2
Tumor heterogeneity may lead to false negative biomarker results if sampling is limited, as reported by the American Society of Clinical Oncology 1
Underestimating the importance of surgical margin status in determining local recurrence risk, as noted by the British Journal of Cancer 4, 3

For HR-positive disease, long-term follow-up is essential as recurrences can occur even after 5 years, as recommended by the American Society of Clinical Oncology 1
Patients with special histologic subtypes of IDC may be candidates for less aggressive therapy due to their favorable prognosis, according to the National Comprehensive Cancer Network 2